Despite progressive improvements in the management of patients with coronavirus disease
2019 (COVID-19), individuals with end-stage kidney disease (ESKD) are still at high risk of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has negatively impacted
on patients of the whole CKD spectrum, causing high rates of morbi-mortality. SARS-CoV-2 …

The CoronaVac vaccine is the most used anti-SARS-CoV-2 vaccine worldwide. Previous
data indicate that this vaccine produces a lower immune response than RNA vaccines such …

Objectives Nursing home (NH) residents have been significantly affected by the coronavirus
disease 2019 (COVID-19) pandemic. Studies addressing the immune responses induced by …

Background The magnitude and durability of cell-mediated immunity in older and severely
frail individuals following coronavirus disease 2019 (COVID-19) vaccination remain unclear …

The effect of a third vaccine dose (3D) of homologous mRNA vaccine on blood levels of
SARS-CoV-2-receptor binding domain (RBD)-total antibodies was assessed in 40 …

Introduction. Patients on peritoneal dialysis (PD) present an impaired humoral response
against SARS-CoV-2, at least after the initial vaccination and booster dose. Until now, the …

Anti-SARS-CoV-2 vaccination of dialysis patients has been proven to be safe and effective
to reduce COVID-19-related morbidity and mortality. However, data on the durability of anti …

Background: Patients with end-stage kidney disease undergoing hemodialysis are
particularly vulnerable to severe COVID-19 as a result of older age and multimorbidities …

Abstract Background and Aims Patients with end stage kidney disease on hemodialysis are
vulnerable to SARS‐CoV‐2 infection. Current guidelines recommend boosters of SARS …